Skip to main content
Top
Published in: Respiratory Research 1/2018

Open Access 01-12-2018 | Research

Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management

Authors: Pere Soler-Palacín, Javier de Gracia, Luis Ignacio González-Granado, Carlos Martín, Carlos Rodríguez-Gallego, Silvia Sánchez-Ramón, Lung ID-Signal Group

Published in: Respiratory Research | Issue 1/2018

Login to get access

Abstract

Background

Pulmonary complications are common in primary immunodeficiency diseases (PID) and contribute to morbidity and mortality in these patients. However, their varied presentation and a general lack of awareness of PID in this setting make early diagnosis and treatment difficult. The aim of this study was to define the warning signs of PID in patients with respiratory manifestations, the necessary diagnostic tests, and the therapeutic management of both children and adults.

Methods

A review of the literature was performed, and 43 PID interdisciplinary specialists were consulted.

Results

This document identifies the pulmonary and extrapulmonary manifestations that should prompt a suspicion of PID, the immunological and respiratory tests that should be included in the diagnostic process according to the level of care, recommendations regarding the use of immunoglobulin replacement therapy according to the specific immunodeficiency, and the minimum recommended immunological and pulmonary monitoring in these patients.

Conclusions

This document is the first to combine scientific evidence with the opinion of a broad panel of experts specializing in the treatment of patients with immunodeficiencies. It aims to provide a useful tool for all practitioners who are regularly involved in the management of these patients.
Literature
1.
go back to reference de Vries E. European Society for Immunodeficiencies m. patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012;167:108–19.CrossRef de Vries E. European Society for Immunodeficiencies m. patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012;167:108–19.CrossRef
2.
go back to reference Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128.CrossRef Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128.CrossRef
3.
go back to reference Costa-Carvalho BT, Grumach AS, Franco JL, et al. Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. J Clin Immunol. 2014;34:10–22.CrossRef Costa-Carvalho BT, Grumach AS, Franco JL, et al. Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. J Clin Immunol. 2014;34:10–22.CrossRef
4.
go back to reference Mahlaoui N, Gathmann B, Kindle G, Ehl S. ESID registry working party steering committee, ESID society. The European Society for Immunodeficiencies (ESID) registry: recent advancements in the epidemiology of primary Immunodeficiencies and how does that translate in clinical care. Int J Public Health. 2014;1:25–7. Mahlaoui N, Gathmann B, Kindle G, Ehl S. ESID registry working party steering committee, ESID society. The European Society for Immunodeficiencies (ESID) registry: recent advancements in the epidemiology of primary Immunodeficiencies and how does that translate in clinical care. Int J Public Health. 2014;1:25–7.
5.
go back to reference Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33:1–7.CrossRef Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33:1–7.CrossRef
6.
go back to reference Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34:954–61.CrossRef Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34:954–61.CrossRef
7.
go back to reference Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104:221–30.CrossRef Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104:221–30.CrossRef
8.
go back to reference Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRef Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRef
9.
go back to reference Roxo Junior P. Primary immunodeficiency diseases: relevant aspects for pulmonologists. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2009;35:1008–17.CrossRef Roxo Junior P. Primary immunodeficiency diseases: relevant aspects for pulmonologists. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2009;35:1008–17.CrossRef
10.
go back to reference Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr. 2014;2:77.CrossRef Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr. 2014;2:77.CrossRef
12.
go back to reference Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. Ann N Y Acad Sci. 2011;1238:7–14.CrossRef Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. Ann N Y Acad Sci. 2011;1238:7–14.CrossRef
13.
go back to reference Subbarayan A, Colarusso G, Hughes SM, et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127:810–6.CrossRef Subbarayan A, Colarusso G, Hughes SM, et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127:810–6.CrossRef
14.
go back to reference Hampson FA, Chandra A, Screaton NJ, et al. Respiratory disease in common variable immunodeficiency and other primary immunodeficiency disorders. Clin Radiol. 2012;67:587–95.CrossRef Hampson FA, Chandra A, Screaton NJ, et al. Respiratory disease in common variable immunodeficiency and other primary immunodeficiency disorders. Clin Radiol. 2012;67:587–95.CrossRef
15.
go back to reference Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med. 2015;3:651–60.CrossRef Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med. 2015;3:651–60.CrossRef
16.
go back to reference Baumann U, Routes JM, Soler-Palacín P, Jolles S. The lung in primary Immunodeficiencies: new concepts in infection and inflammation. Front Immunol. 2018;9:1837.CrossRef Baumann U, Routes JM, Soler-Palacín P, Jolles S. The lung in primary Immunodeficiencies: new concepts in infection and inflammation. Front Immunol. 2018;9:1837.CrossRef
17.
go back to reference Serra G, Milito C, Mitrevski M, et al. Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity. Chest. 2011;140:1581–9.CrossRef Serra G, Milito C, Mitrevski M, et al. Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity. Chest. 2011;140:1581–9.CrossRef
18.
go back to reference Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396–414.CrossRef Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396–414.CrossRef
19.
go back to reference Nonas S. Pulmonary manifestations of primary immunodeficiency disorders. Immunol Allergy Clin N Am. 2015;35:753–66.CrossRef Nonas S. Pulmonary manifestations of primary immunodeficiency disorders. Immunol Allergy Clin N Am. 2015;35:753–66.CrossRef
20.
go back to reference Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012;148:79–84.CrossRef Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012;148:79–84.CrossRef
21.
go back to reference Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361:2046–55.CrossRef Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361:2046–55.CrossRef
22.
go back to reference Al-Herz W, Nanda A. Skin manifestations in primary immunodeficient children. Pediatr Dermatol. 2011;28:494–501.CrossRef Al-Herz W, Nanda A. Skin manifestations in primary immunodeficient children. Pediatr Dermatol. 2011;28:494–501.CrossRef
23.
go back to reference Kobrynski LJ, Mayer L. Diagnosis and treatment of primary immunodeficiency disease in patients with gastrointestinal symptoms. Clin Immunol. 2011;139:238–48.CrossRef Kobrynski LJ, Mayer L. Diagnosis and treatment of primary immunodeficiency disease in patients with gastrointestinal symptoms. Clin Immunol. 2011;139:238–48.CrossRef
24.
go back to reference Cunningham-Rundles C. Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin Exp Immunol 2011;164 Suppl 2:6–11.CrossRef Cunningham-Rundles C. Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin Exp Immunol 2011;164 Suppl 2:6–11.CrossRef
25.
go back to reference Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol. 2008;28(Suppl 1):S11–9.CrossRef Moraes-Vasconcelos D, Costa-Carvalho BT, Torgerson TR, Ochs HD. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol. 2008;28(Suppl 1):S11–9.CrossRef
26.
go back to reference Arason GJ, Jorgensen GH, Ludviksson BR. Primary immunodeficiency and autoimmunity: lessons from human diseases. Scand J Immunol. 2010;71:317–28.CrossRef Arason GJ, Jorgensen GH, Ludviksson BR. Primary immunodeficiency and autoimmunity: lessons from human diseases. Scand J Immunol. 2010;71:317–28.CrossRef
28.
go back to reference Jolles S, Borrell R, Zouwail S, et al. Calculated globulin (CG) as a screening test for antibody deficiency. Clin Exp Immunol. 2014;177:671–8.CrossRef Jolles S, Borrell R, Zouwail S, et al. Calculated globulin (CG) as a screening test for antibody deficiency. Clin Exp Immunol. 2014;177:671–8.CrossRef
29.
go back to reference Pecoraro A, Jolles S, Crescenzi L, et al. Validation of calculated globulin (CG) as a screening test for antibody deficiency in an Italian University hospital. Curr Pharm Biotechnol. 2018. Pecoraro A, Jolles S, Crescenzi L, et al. Validation of calculated globulin (CG) as a screening test for antibody deficiency in an Italian University hospital. Curr Pharm Biotechnol. 2018.
30.
go back to reference Garcia-Prat M, Vila-Pijoan G, Martos Gutierrez S, et al. Age-specific pediatric reference ranges for immunoglobulins and complement proteins on the Optilite. J Clin Lab Anal. 2018:e22420.CrossRef Garcia-Prat M, Vila-Pijoan G, Martos Gutierrez S, et al. Age-specific pediatric reference ranges for immunoglobulins and complement proteins on the Optilite. J Clin Lab Anal. 2018:e22420.CrossRef
31.
go back to reference Ozerovitch L. Primary immune deficiency in bronchiectasis. Nurs Times. 2016;112:16–9.PubMed Ozerovitch L. Primary immune deficiency in bronchiectasis. Nurs Times. 2016;112:16–9.PubMed
32.
go back to reference Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM. 2002;95:655–62.CrossRef Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM. 2002;95:655–62.CrossRef
33.
go back to reference Sala Cunill A, Soler-Palacín P, Martín De Vicente C, Labrador Horrillo M, Luengo Sánchez O, Figueras Nadal C. Common variable immunodeficiency. Prognostic factors for lung damage Med Clin (Barc). 2010;134:64–7.CrossRef Sala Cunill A, Soler-Palacín P, Martín De Vicente C, Labrador Horrillo M, Luengo Sánchez O, Figueras Nadal C. Common variable immunodeficiency. Prognostic factors for lung damage Med Clin (Barc). 2010;134:64–7.CrossRef
34.
go back to reference Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1–s46.CrossRef Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1–s46.CrossRef
35.
go back to reference Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.CrossRef Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.CrossRef
36.
go back to reference Jolles S. Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol. 2014;178(Suppl 1):67–9.CrossRef Jolles S. Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol. 2014;178(Suppl 1):67–9.CrossRef
37.
go back to reference Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr Infect Dis. 2010;57:185–218. Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr Infect Dis. 2010;57:185–218.
38.
go back to reference Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354–1360 e4.CrossRef Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354–1360 e4.CrossRef
39.
go back to reference Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6:553–67.CrossRef Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6:553–67.CrossRef
40.
go back to reference Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am. 2008;28:779–802 viii.CrossRef Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am. 2008;28:779–802 viii.CrossRef
41.
go back to reference Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.CrossRef Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.CrossRef
42.
go back to reference Haddad É, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46:315–21.CrossRef Haddad É, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46:315–21.CrossRef
43.
go back to reference Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.CrossRef Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.CrossRef
44.
go back to reference Thépot S, Malphettes M, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol. 2010;30:602–6.CrossRef Thépot S, Malphettes M, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol. 2010;30:602–6.CrossRef
45.
go back to reference Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73:1307–19.CrossRef Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73:1307–19.CrossRef
46.
go back to reference Berger M, Murphy E, Riley P, Bergman GE, Investigators VT. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103:856–63.CrossRef Berger M, Murphy E, Riley P, Bergman GE, Investigators VT. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103:856–63.CrossRef
47.
go back to reference Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.CrossRef Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.CrossRef
48.
go back to reference Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:27.CrossRef Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:27.CrossRef
49.
go back to reference Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146–60.CrossRef Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146–60.CrossRef
50.
go back to reference Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.CrossRef Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.CrossRef
51.
go back to reference Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Suppl 1):51–9.CrossRef Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(Suppl 1):51–9.CrossRef
52.
go back to reference Bourdin A, Berger J, Früh A, Spertini F, Bugnon O. Subcutaneous immunoglobulin and support program: what level of interest of patients? Rev Med Suisse. 2015;11:831–5.PubMed Bourdin A, Berger J, Früh A, Spertini F, Bugnon O. Subcutaneous immunoglobulin and support program: what level of interest of patients? Rev Med Suisse. 2015;11:831–5.PubMed
53.
go back to reference Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014;34:1015–7.CrossRef Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014;34:1015–7.CrossRef
54.
go back to reference Chinen J, Anmuth D, Franklin AR, Shearer WT. Long-term follow-up of patients with primary immunodeficiencies. J Allergy Clin Immunol. 2007;120:795–7.CrossRef Chinen J, Anmuth D, Franklin AR, Shearer WT. Long-term follow-up of patients with primary immunodeficiencies. J Allergy Clin Immunol. 2007;120:795–7.CrossRef
55.
go back to reference Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94:S1–63.CrossRef Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94:S1–63.CrossRef
56.
go back to reference Tarzi MD, Grigoriadou S, Carr SB, Kuitert LM, Longhurst HJ. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol. 2009;155:147–55.CrossRef Tarzi MD, Grigoriadou S, Carr SB, Kuitert LM, Longhurst HJ. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol. 2009;155:147–55.CrossRef
57.
go back to reference Jolles S, Sánchez-Ramón S, Quinti I, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190:226–34.CrossRef Jolles S, Sánchez-Ramón S, Quinti I, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190:226–34.CrossRef
Metadata
Title
Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management
Authors
Pere Soler-Palacín
Javier de Gracia
Luis Ignacio González-Granado
Carlos Martín
Carlos Rodríguez-Gallego
Silvia Sánchez-Ramón
Lung ID-Signal Group
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2018
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-018-0923-8

Other articles of this Issue 1/2018

Respiratory Research 1/2018 Go to the issue